Clinical trial

Rifaximin SSD in Dementia Trial

NCT06718686

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-12-30

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2024-12-30Date precision: day

Registry last updated2026-04-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Dementia Alzheimer Typeunresolved

Dementia Associated With Cerebrovascular Diseaseunresolved

Interventions

Rifaximin SSD 40 mg IR tabletDRUG

PlaceboDRUG

Sponsors & collaborators

Jasmohan Bajajlead sponsor

Bausch Health Americas, Inc.collaborator

Mapped research locations

RichmondVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06718686 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.